|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
MXPA05008156A
(es)
*
|
2003-02-01 |
2005-09-30 |
Neuralab Ltd |
Inmunizacion activa para generar anticuerpos para beta-a soluble.
|
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
|
CA2582194A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Neuralab Limited |
Methods and compositions for improving recombinant protein production
|
|
PE20061329A1
(es)
|
2004-12-15 |
2006-12-08 |
Neuralab Ltd |
Anticuerpos ab humanizados para mejorar la cognicion
|
|
ES2396555T3
(es)
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
BRPI0611600B8
(pt)
|
2005-06-17 |
2021-05-25 |
Wyeth Corp |
método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
|
|
TW200806317A
(en)
*
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
CN101553504A
(zh)
*
|
2006-12-11 |
2009-10-07 |
豪夫迈·罗氏有限公司 |
Aβ抗体胃肠外制剂
|
|
AU2008204335B2
(en)
|
2007-01-11 |
2013-06-13 |
Michael Bacher |
Diagnosis and treatment of Alzheimer's and other neurodementing diseases
|
|
NZ598881A
(en)
*
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
SI2182983T1
(sl)
|
2007-07-27 |
2014-09-30 |
Janssen Alzheimer Immunotherapy |
Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
|
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
EP3381445B1
(en)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
KR20210049186A
(ko)
*
|
2007-11-30 |
2021-05-04 |
애브비 바이오테크놀로지 리미티드 |
단백질 제형 및 이의 제조방법
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
NZ587632A
(en)
|
2008-03-14 |
2012-06-29 |
Biocon Ltd |
An anti-cd6 monoclonal antibody and a method thereof
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
WO2010100135A1
(en)
*
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
EP2453874A2
(en)
*
|
2009-07-14 |
2012-05-23 |
Biogen Idec MA Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US20130028933A1
(en)
*
|
2009-12-28 |
2013-01-31 |
Ligocyte Pharmaceuticals, Inc. |
Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
|
|
CN102686241A
(zh)
*
|
2009-12-29 |
2012-09-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
|
RS59830B1
(sr)
|
2010-03-01 |
2020-02-28 |
Bayer Healthcare Llc |
Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
|
|
JP5960120B2
(ja)
|
2010-03-31 |
2016-08-02 |
スタビリテック リミテッド |
ウイルス粒子の安定化
|
|
JP5869553B2
(ja)
|
2010-03-31 |
2016-02-24 |
スタビリテック リミテッド |
ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
|
|
GB2499480A
(en)
|
2010-03-31 |
2013-08-21 |
Stabilitech Ltd |
Method for preserving alum adjuvants and alum-adjuvanted vaccines
|
|
PT3170508T
(pt)
|
2010-06-04 |
2020-01-16 |
Wyeth Llc |
Formulações de vacinas
|
|
CN103458926B
(zh)
|
2010-11-11 |
2016-10-26 |
艾伯维生物技术有限公司 |
改进的高浓度抗TNF α 抗体液体制剂
|
|
EP2471554A1
(en)
*
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
|
EP2500035A1
(en)
*
|
2011-03-15 |
2012-09-19 |
Icon Genetics GmbH |
Pharmaceutical formulation containing immunglobulin
|
|
MX341076B
(es)
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
|
GB201117233D0
(en)
|
2011-10-05 |
2011-11-16 |
Stabilitech Ltd |
Stabilisation of polypeptides
|
|
JP2015526409A
(ja)
*
|
2012-07-03 |
2015-09-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｃ−末端及び中心エピトープａ−ベータ抗体
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
KR102405247B1
(ko)
|
2013-07-23 |
2022-06-07 |
바이오콘 리미티드 |
Cd6 결합 파트너의 용도 및 이에 기초한 방법
|
|
IL312865B2
(en)
*
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
|
GB201320660D0
(en)
*
|
2013-11-22 |
2014-01-08 |
Qualasept Ltd |
Method
|
|
GB201406569D0
(en)
|
2014-04-11 |
2014-05-28 |
Stabilitech Ltd |
Vaccine compositions
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
CR20210429A
(es)
|
2015-06-24 |
2021-09-24 |
Hoffmann La Roche |
ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
TWI819458B
(zh)
|
2015-10-02 |
2023-10-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
GB201604124D0
(en)
*
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
CN107446044B
(zh)
*
|
2016-05-30 |
2021-04-30 |
越海百奥药业(绍兴)有限公司 |
一种纯化抗体的方法及所用缓冲液
|
|
CN109843266B
(zh)
*
|
2016-08-02 |
2023-08-11 |
安巴知识产权有限公司 |
稳定的布洛芬注射组合物
|
|
PL3529274T3
(pl)
|
2016-10-21 |
2024-09-09 |
Biocon Limited |
Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
|
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
|
GB201703063D0
(en)
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
GB2562241B
(en)
|
2017-05-08 |
2022-04-06 |
Stabilitech Biopharma Ltd |
Vaccine compositions
|
|
AU2018321335B2
(en)
*
|
2017-08-22 |
2025-08-14 |
Biogen Ma Inc. |
Pharmaceutical compositions containing anti-beta amyloid antibodies
|
|
MX2020005981A
(es)
|
2017-12-08 |
2020-08-24 |
Argenx Bvba |
Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
|
|
EP3802590A2
(en)
*
|
2018-06-08 |
2021-04-14 |
Argenx BVBA |
Compositions and methods for treating immune thrombocytopenia
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
GB201906917D0
(en)
*
|
2019-05-16 |
2019-07-03 |
Intract Pharma Ltd |
Novel compositions
|
|
KR20220148804A
(ko)
|
2020-01-08 |
2022-11-07 |
아르젠엑스 비브이 |
천포창 장애의 치료 방법
|
|
CN112451652A
(zh)
*
|
2020-12-07 |
2021-03-09 |
苏州智核生物医药科技有限公司 |
一种重组人促甲状腺素注射液
|
|
CA3258004A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN/HSA BONDING MOLECULES AND METHODS OF USE
|